Facebook
Twitter
LinkedIn
Forward
Person-Centered Care Approaches to the Treatment of Patients With Neuropsychiatric Manifestations of Parkinson’s Disease (Archived CME/CE Monograph)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
This educational activity is intended to help psychiatric clinicians treat complex patients. Experts provide guidance through cases and discussion that gives a systematic approach to managing patients with Parkinson’s disease and comorbid conditions, such as dementia, anxiety, psychosis, depression, and anxiety. The desired results of this activity are for psychiatric clinicians to understand the treatments available and develop evidence-based treatment plans for complex patients while maintaining the safety and quality of life of patients.
Target Audience
This educational activity is intended for psychiatric clinicians, including physicians, physician assistants, nurse practitioners, and nurses, caring for patients with Parkinson’s disease.
Learning Objectives
After completing this activity, participants will be better able to:
- Describe the use of behavioral management strategies to manage neuropsychiatric aspects of Parkinson’s disease
- Develop evidence-based treatment strategies for patients with Parkinson’s disease and comorbid neuropsychiatric conditions (eg, Parkinson’s disease psychosis, Parkinson’s disease dementia, depression, anxiety, and agitation)
Faculty
 | George T. Grossberg, MD (Chair) Samuel W. Fordyce Professor Director, Geriatric Psychiatry Department of Psychiatry and Behavioral Neuroscience Saint Louis University School of Medicine St Louis, Missouri |
 | Danielle N. Larson, MD Movement Disorders Specialist Ken and Ruth Davee Department of Neurology Northwestern University Feinberg School of Medicine Chicago, Illinois |
 | Gary Small, MD Chair of Psychiatry Hackensack University Medical Center Physician-in-Chief, Behavioral Health H. Hovnanian Family Foundation Chair Hackensack Meridian Health Professor of Psychiatry and Behavioral Health Hackensack Meridian School of Medicine Hackensack, New Jersey |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
George T. Grossberg, MD, is a consultant for ACADIA Pharmaceuticals Inc, Alkahest, Inc, Avanir Pharmaceuticals, Inc, Axsome Therapeutics, Inc, Biogen Idec, BioXcel Therapeutics, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc, H Lundbeck A/S, Karuna Therapeutics, Otsuka America Pharmaceutical, Inc, and Takeda Pharmaceuticals USA, Inc; is a contracted researcher for F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Inc, and Nia Therapeutics; and is on the safety monitoring committee of Anavex Life Sciences Corp, EryDel SPA, Intra-Cellular Therapies, Inc, Merck & Co., Inc, and Newron Pharmaceuticals SPA.
Danielle N. Larson, MD, is an advisory board member of Kyowa Kirin Co, Ltd.
Gary Small, MD, is a consultant for Eli Lilly and Company, Handok Inc, and Theravalues; is an advisory board member of ACADIA Pharmaceuticals Inc, Biogen Idec, Corium, Inc, F. Hoffmann-La Roche Ltd, Herbalife International of America, Inc, H Lundbeck A/S*, McCormick Science Institute, Otsuka America Pharmaceutical, Inc, and Reckitt Benckiser Group PLC; and has stock options in CereMark Pharma that have not been exercised.
* The financial relationship existed during the past 24 months but has now ended.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Other MedEdicus and Amedco planners, managers, and writers have no relevant commercial relationships to disclose.
Satisfactory Completion
Learners must take the pretest, read the monograph, and complete the posttest and evaluation form to receive a certificate of completion. You must complete the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
For Physicians
ACCME Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For Nurses
Interprofessional Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by MedEdicus LLC and Amedco LLC. Amedco LLC is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.5 ANCC contact hours.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing inforation for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Amedco LLC, or ACADIA Pharmaceuticals Inc.
©2023 MedEdicus LLC. 292.3